Lupin Ltd Q3 FY2026 Concall Summary

Key Takeaways

• Record US quarter, broad-based growth: US sales hit an all-time high of \$350 mn, driven by new exclusivity products and base business volume, while India, Europe, LATAM and Emerging Markets all delivered double-digit YoY growth.
• Margins surged on mix and operating leverage: Gross margin expanded 420 bps YoY to 73.5%, and EBITDA margin reached 31.1% vs 24.3% last year, prompting management to raise full-year EBITDA guidance to 27%-28%.
• Biosimilars inflection point reached: First US biosimilar approval (Pegfilgrastim) with launch imminent, a deepening pipeline, and a selective first-wave strategy mark a shift from cautious to confident on the opportunity.
• FY27 margin reset is priced in: Management guided FY27 EBITDA margins to 24%-25%, a deliberate step down from FY26's elevated level as competition enters for some products, while top-line momentum is expected to continue.
• What to watch next quarter: The Pegfilgrastim launch trajectory, the Semaglutide day-one India launch, VISUfarma consolidation, and any competitor entry into Tolvaptan.

US Business: The Billion-Dollar Runway

• Record quarter built on exclusivity and volume: US revenue reached \$350 mn, the highest ever, with Tolvaptan (sole generic on market) and generic Risperdal Consta (CGT exclusivity) as headline new-product drivers. Base business volumes and seasonal tailwinds more than offset low single-digit price erosion.
• Mirabegron settlement removes a cloud: A \$90 mn total payout (\$15 mn provisioned for the past, \$75 mn spread to September '27) eliminates litigation risk and secures uninterrupted market access. The future-linked portion is a license amortized over time, hitting P&L but not EBITDA, and management still views the product as a very attractive contributor.
• Tolvaptan competition is delayed, not absent: Lupin crossed IP hurdles others have not, and manufacturing complexity adds a barrier. Other competitors face 30-month stays into November '26 and beyond, so competition is likely to be staggered rather than a sudden cliff.
• Seasonality will normalize: Tolvaptan and Mirabegron were larger QoQ contributors, but Albuterol, Tiotropium and Oseltamivir also grew on seasonality, an effect that should unwind over the next two quarters.
• Complex products share set to double: The pipeline spans injectables (ramping to USD 100 mn+ over three years), respiratory products, first-to-files including Xywav (FY29 launch), and 505(b)(2) products (first launch FY27). Institutional business is expected to build materially over three to five years.

Vinita Gupta: "We have multiple growth drivers at this point for the organization and feel fairly confident that we can one, sustain this billion plus revenue level over the next couple of years and build from there as we bring material biosimilars, respiratory products, as well as injectables, including the other first to files that we have in our portfolio to market." [8-9]

India & Emerging Markets: Outperformance Embedded

• India prescription business growing ahead of the market: Core prescription growth was 10.9% YoY in Q3, with nine-month growth at 9.4% broadly in line with IPM's 9.3%. Excluding LOE on Gibtulio and Ajaduo, domestic growth was 11.2% for nine months. Volume growth was strong at 5.6%, with new products adding 1.5%.
• Chronic portfolio deepening: Chronic therapies now represent 67% of the India portfolio, up from 65% last quarter. Cardiac and Respiratory are growing at 1.3x and 1.6x their respective market growth rates.
• Obesity division built ahead of the molecule: Lupin launched a dedicated obesity division engaging diabetologists, cardiologists and gastroenterologists, positioning for a day-one launch of injectable Semaglutide. A strategic partnership with Gan & Lee for Bofanglutide, a novel fortnightly GLP-1 agonist, further strengthens the diabetes and obesity portfolio. [3-4]
• Semaglutide opportunity sized cautiously: Management estimates an INR 1,500 crore market in year one, with Lupin capturing INR 50-60 crores. Supply is not a concern, and the company expects to be present on day one, leveraging its large cardio-metabolic franchise for prescription share.
• Emerging Markets surged 42% YoY: Brazil nearly doubled in local currency on successful Dapagliflozin commercialization, with Mexico and the Philippines also contributing, offsetting tempered performance in South Africa. The Dapagliflozin lineup is expected to sustain momentum.
• Salesforce investment supports the growth ambition: 900 people were added to the salesforce in the last six months, taking the total to over 11,000, with a pipeline of more than 80 new product launches over coming years. Management expects to continue growing 20%-30% ahead of the market, with double-digit growth assured for the next couple of years.

Nilesh Gupta: "I think 20% - 30% ahead of the market is what we would see ourselves at. The market is growing strong, so double-digit growth is assured. And I think not just for the next couple of quarters, but I think for the next couple of years we would expect to continue growth."

Biosimilars: From Cautious to Committed

• Pegfilgrastim approval marks the turning point: A successful US FDA inspection of the Pune biologics facility with zero observations was followed by approval of Lupin's first US biosimilar. An exclusive licensing agreement with Valorum (staffed by ex-McKesson and AmerisourceBergen specialty distribution experts) is in place, and launch is expected before the end of Q4 FY26.
• Pipeline depth is building: Ranibizumab is hopefully launchable in FY27. On-body Pegfilgrastim is making good progress. Aflibercept and Etanercept are targeted for CY29 (FY30). Mepolizumab is also in the pipeline. Per an analyst's math, Pegfilgrastim, Ranibizumab and Aflibercept together could contribute ~USD 100 mn in the next 2-3 years, a potential management confirmed.
• Selective first-wave strategy: Lupin targets programs where it can be in the first wave, one of few players based on technology advantage or other barriers. The company is building a commercial front-end across three therapy areas to leverage across both biosimilars and branded specialty products. Few biosimilar companies operate at scale globally, so the competitive intensity is lower than in small-molecule generics.
• PBM dynamics are an opportunity, not a threat: Private-label biosimilars through PBMs (e.g., Cordavis for Humira) have driven significant share for players like Sandoz. Lupin sees this as an avenue to gain share as PBMs partner with biosimilar manufacturers to bring access, even as the PBM block itself declines.

Vinita Gupta: "I'd say a couple of years ago, we were not very gung-ho on biosimilars, but today we see significant potential with Pegfilgrastim to start with, but also the other biosimilars that we have in our pipeline."

Margins: FY26 Peak, FY27 Reset, Long-Term Levers

• FY26 margin delivery is ahead of plan: Gross margin expanded 420 bps YoY to 73.5%, driven by better product mix, lower share of in-licensed products (including higher-profitability and LOE products in India), increased volumes and cost efficiencies. EBITDA margin reached 31.1% vs 24.3% last year, and nine-month EBITDA margins stand at 29.8% vs 24%.
• Full-year guidance raised: Management now expects FY26 EBITDA margins of 27%-28%, up from the earlier 25%-26%, with Q4 tempered by higher R&D expenditure and lower PLI income. R&D spend is expected at 7.5%-8.5% of sales for the full year.
• FY27 margin guided down deliberately: EBITDA margins are expected at 24%-25%, a reset driven by anticipated competition for some products. Top-line buoyancy is expected to continue, supported by Mirabegron's fresh lease of life, Tolvaptan's ongoing exclusivity, new product launches, the Semaglutide opportunity, and Emerging Markets momentum. Cost initiatives will aim to maintain gross and EBITDA margins.
• VISUfarma adds revenue, margin accretion to follow: The European ophthalmology acquisition (EUR 60 mn+ revenue) is expected to close in the coming weeks and consolidate from Q4. Starting margins are ~25%, with cost synergies expected to lift that higher over time.
• R&D intensity sustained at the high end: At 7.5% of sales, Lupin's R&D spend is among the highest in Indian pharma, with almost 70% directed toward the complex portfolio (injectables, inhalations, drug-device combinations with clinical trials, biosimilars, specialty). In absolute terms R&D will keep rising; as a percentage of sales it may stagnate. The generics share of R&D (Para-IIIs, Para-IVs, oral solids) is declining in both absolute and percentage terms.

Specialty & Capital Allocation: Building the Next Leg

• Specialty ambitions are taking shape across three therapy areas: Respiratory (leveraging current position), Neurology (NaMuscla as a starting point, with plans to bring it to the US and add other products), and Ophthalmology (starting in Europe with VISUfarma, with appetite for additional assets in Europe, the US and other developed markets).
• M&A sweet spot defined: Top priority is specialty assets with a sweet spot of USD 250-300 mn, potentially higher for the right proposition. The same range applies to India assets. The search spans the US, Europe and other developed markets, and includes clinical-stage assets (Phase III or completed Phase II ready for Phase III) that will require further investment.
• Balance sheet capacity is ample: Management stated the ability to borrow USD 1.5-1.6 bn, beyond existing cash on the balance sheet, providing significant firepower for strategic capital allocation.

Ramesh Swaminathan: "We have the ability to borrow about USD 1.5 billion - 1.6 billion, so to speak, apart from of course what we have on our balance sheet in terms of cash already."

Regulatory & Operational Excellence

• Clean regulatory record sustained: The Nagpur Unit-1 facility received NAI status with zero observations, and EIRs were issued for Nagpur Unit-2 injectables and the Aurangabad facility, reinforcing manufacturing compliance credibility.
• ESG leadership recognized: Lupin achieved the highest A-leadership rating from CDP for both climate change and water security, and its greenhouse gas emissions reduction targets were formally approved by SBTi.
• AI adoption beginning across functions: Pilot projects are expected to be implemented over the next nine to twelve months across finance, HR, legal and procurement, though no financial impact has been quantified.

Guidance & Commitments

Key Metrics